Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences

BOSTON, MA, Sep. 8, 2020 – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information about edasalonexent, in Phase 3 development for the treatment of Duchenne muscular dystrophy, at the following virtual investor conferences this month:

- HC Wainwright 22nd Annual Global Investment Conference on Monday, September 14th, at 4:00pm EDT

- Cantor Virtual Healthcare Conference on Wednesday, September 16th, at 3:20pm EDT

Catabasis will also be participating in the Oppenheimer Virtual Fall Healthcare, Life Sciences, & MedTech Summit, which will take place from September 21st – 23rd, 2020.

Live webcasts of the events can be accessed from the investors section of www.catabasis.com. Archived replays will also be available for 30 days following the event.

About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule designed to inhibit NF-kB that is being developed as a potential foundational therapy for all patients affected by DMD, regardless of their underlying mutation. In DMD the loss of dystrophin leads to chronic activation of NF-kB, which is a key driver of skeletal and cardiac muscle disease progression. The ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy and safety of edasalonexent for registration purposes. Edasalonexent is also being evaluated in the GalaxyDMD open-label extension trial. In the MoveDMD Phase 2 trial and open-label extension, the Company observed that edasalonexent preserved muscle function and substantially slowed disease progression compared to rates of change in a control period, and significantly improved biomarkers of muscle health and inflammation. The FDA has granted orphan drug, fast track, and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results, please visit www.catabasis.com.

About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

Catabasis Contacts:

Investor relations:
Andrea Matthews
investors@catabasis.com

Media:
Elizabeth Higgins
media@catabasis.com